Xin Lang Cai Jing·2026-01-09 06:58Group 1 - The core viewpoint of the news is that Dize Pharmaceutical has seen a stock price increase of 5.2%, reaching 66.75 yuan per share, with a total market capitalization of 30.784 billion yuan [1] - Dize Pharmaceutical, established on October 27, 2017, focuses on the research and industrialization of innovative drugs, with its main business revenue entirely derived from drug sales [1] - The company is located in Wuxi, Jiangsu Province, and has been publicly listed since December 10, 2021 [1] Group 2 - From the perspective of fund holdings, Dize Pharmaceutical is a significant position in the portfolio of Guotai Haitong Asset Management, specifically in the Guotai Haitong Innovation Pharmaceutical Mixed Fund A (014157), which reduced its holdings by 30,000 shares to 97,800 shares, representing 4.8% of the fund's net value [2] - The Guotai Haitong Innovation Pharmaceutical Mixed Fund A was established on December 23, 2021, with a current scale of 1.05 billion yuan, achieving a year-to-date return of 7.43% and a one-year return of 23.95% [2] - The fund manager, Li Zibo, has been in charge for 4 years and 19 days, with the fund's total asset size at 3.067 billion yuan, achieving a best return of 40.16% and a worst return of -10.63% during his tenure [3]